After Stopping Weight-Loss Injections, a Daily Pill Kept More of the Weight Off

CATEGORY: DIET & WEIGHT

People taking weight-loss injections eventually face the same question: what happens when the shots end? A year-long randomized trial put 376 adults on either a once-daily tablet or a placebo the moment their injections stopped. The tablet group held on to 75% to 79% of the weight they had lost. The placebo group kept 38% to 49% of it.¹ The tablet was orforglipron, the first weight-loss medicine of its kind that comes as an ordinary pill rather than an injection.

Everyone Arrived Having Already Lost Weight

Each participant had just finished 72 weeks in an earlier trial, losing at least 5% of their body weight on one of the two leading injectables, tirzepatide or semaglutide. Both imitate GLP-1, a gut hormone that signals fullness to the brain, which is why appetite tends to return once the medicine stops. At 29 US sites, a blinded draw split those 376 adults between the orforglipron tablet and a dummy pill of matching appearance. Who got which stayed hidden from participants and investigators alike. Weight was then tracked for 52 more weeks.

Most of the Loss Held, and Some Kept Falling

Among former tirzepatide users, the pill group kept 74.7% of their lost weight after a year, against 49.2% on placebo, a gap of 25.5 percentage points. Among former semaglutide users the gap ran wider: 79.3% against 37.6%, a difference of 41.7 percentage points.¹ The pill groups did not merely coast. On average they drifted a little further down over the year, roughly another 5% of body weight among former tirzepatide users and about 1% among former semaglutide users, while the placebo groups steadily regained. Picture a relay. The injection ran the first leg and the tablet took the baton without dropping it.

The Handoff the Researchers Worried About

The team put its expectation on record in advance. It thought people coming off tirzepatide would regain more, because tirzepatide works on two gut-hormone systems at once while orforglipron works on only one, making that switch a step down in drug power. The results bore this out only partly. Former tirzepatide users did keep a smaller share of their loss than former semaglutide users. Even so, the pill preserved roughly three quarters of the result after the tougher handoff.¹

Side Effects, and What Stopping Altogether Looks Like

The side effects were this drug family’s usual ones: nausea, constipation, vomiting and diarrhea, mostly mild to moderate. Between 4.8% and 7.3% of pill takers stopped because of them, and one case of mild pancreatitis, inflammation of the pancreas, occurred.¹ The placebo groups show what tends to happen with no medicine at all, and that matches earlier evidence. In a separate randomized trial, people who came off tirzepatide onto placebo regained an average of 14% of body weight within a year, while those who stayed on the drug lost a further 5.5%.² Obesity behaves like a chronic condition, and the benefit of these medicines is tied to staying on some form of treatment. What the new trial adds is that the treatment which continues need not be an injection.

Key Takeaways

• Adults who moved from tirzepatide or semaglutide injections straight to the daily orforglipron tablet kept 75% to 79% of their lost weight over a year; those moved to placebo kept 38% to 49%.
• The trial was double-blind and randomized across 376 adults, so the comparison reflects the pill itself rather than differences in who chose it.
• One year is all it measured. How long maintenance lasts past that is unknown, and the pill groups still had the drug family’s typical stomach-related side effects.
• Earlier research found that stopping these medicines entirely is usually followed by substantial regain, which is what the placebo groups here also showed.

References

1. Aronne LJ, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine. 2026;32(7):2679–2687. link
2. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. link